DE602007005671D1 - Aminomethyl-2-imidazole mit affinität zu mit dem trace-amin assoziierten rezeptoren - Google Patents

Aminomethyl-2-imidazole mit affinität zu mit dem trace-amin assoziierten rezeptoren

Info

Publication number
DE602007005671D1
DE602007005671D1 DE602007005671T DE602007005671T DE602007005671D1 DE 602007005671 D1 DE602007005671 D1 DE 602007005671D1 DE 602007005671 T DE602007005671 T DE 602007005671T DE 602007005671 T DE602007005671 T DE 602007005671T DE 602007005671 D1 DE602007005671 D1 DE 602007005671D1
Authority
DE
Germany
Prior art keywords
amin
aminomethyl
imidazole
affinity
trace
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007005671T
Other languages
English (en)
Inventor
Guido Galley
Annick Goergler
Zbinden Katrin Groebke
Roger Norcross
Henri Stalder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38819769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602007005671(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602007005671D1 publication Critical patent/DE602007005671D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE602007005671T 2006-10-19 2007-10-09 Aminomethyl-2-imidazole mit affinität zu mit dem trace-amin assoziierten rezeptoren Active DE602007005671D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06122553 2006-10-19
PCT/EP2007/060664 WO2008046756A1 (en) 2006-10-19 2007-10-09 Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors

Publications (1)

Publication Number Publication Date
DE602007005671D1 true DE602007005671D1 (de) 2010-05-12

Family

ID=38819769

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007005671T Active DE602007005671D1 (de) 2006-10-19 2007-10-09 Aminomethyl-2-imidazole mit affinität zu mit dem trace-amin assoziierten rezeptoren

Country Status (21)

Country Link
US (1) US20080096906A1 (de)
EP (1) EP2076496B1 (de)
JP (1) JP5167265B2 (de)
KR (1) KR101172940B1 (de)
CN (1) CN101528709B (de)
AR (1) AR063326A1 (de)
AT (1) ATE462696T1 (de)
AU (1) AU2007312389B2 (de)
BR (1) BRPI0718059A2 (de)
CA (1) CA2665255A1 (de)
CL (1) CL2007002970A1 (de)
DE (1) DE602007005671D1 (de)
ES (1) ES2340223T3 (de)
IL (1) IL197872A (de)
MX (1) MX2009003887A (de)
NO (1) NO20091480L (de)
PE (1) PE20080984A1 (de)
RU (1) RU2009112495A (de)
TW (1) TW200835494A (de)
WO (1) WO2008046756A1 (de)
ZA (1) ZA200902279B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1976828T (pt) 2005-12-29 2017-03-10 Celtaxsys Inc Derivados de diamina como inibidores de leucotrieno a4 hidrolase
RU2439062C2 (ru) * 2006-10-19 2012-01-10 Ф.Хоффманн-Ля Рош Аг Производные имидазолона и имидазолидинона как 11в-hsd1 ингибиторы при диабете
EP2076497B1 (de) 2006-10-19 2012-02-22 F. Hoffmann-La Roche AG Aminomethyl-4-imidazole
JP2010534701A (ja) * 2007-07-27 2010-11-11 エフ．ホフマン−ラ ロシュ アーゲー Ｔａａｒリガンドとしての２−アゼチジンメタンアミン及び２−ピロリジンメタンアミン
US8242153B2 (en) * 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
EP2968359B1 (de) 2013-03-12 2021-01-20 Celltaxis, LLC Verfahren zur hemmung einer leukotrien-a4-hydrolase
AU2014239567B2 (en) 2013-03-14 2017-12-14 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase
WO2014152536A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
JP2016513681A (ja) 2013-03-14 2016-05-16 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素の阻害剤
JP7386815B2 (ja) 2018-05-31 2023-11-27 セルタクシー、エルエルシー 呼吸器疾患患者の肺増悪を軽減する方法
CN115073273A (zh) * 2021-03-15 2022-09-20 中国医学科学院药物研究所 二苯烷类化合物及其制备方法、药物组合物和用途
US20240190888A1 (en) * 2021-03-29 2024-06-13 Shujing Biopharma Co., Ltd Spiro-containing derivative, and preparation method therefor and use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2731471A (en) * 1956-01-17 Nxg hi
US2161938A (en) * 1934-07-31 1939-06-13 Soc Of Chemical Ind Imidazolines
US2457047A (en) * 1946-02-13 1948-12-21 Monsanto Chemicals 2-(2'-thenyl)-4, 5-dihydroimidazoles and process for making the same
US2778836A (en) * 1954-04-02 1957-01-22 Union Chimique Belge Sa Substituted 2-methyl-delta2 imidazolines
US2744909A (en) * 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-phenylbenzyl) imidazoline and acid addition salts
US2744910A (en) * 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-benzylbenzyl)-imidazoline and acid addition salts
US2919274A (en) * 1957-09-17 1959-12-29 Sahyun Melville Amidines
DE1121054B (de) * 1960-11-23 1962-01-04 Merck Ag E Verfahren zur Herstellung eines neuen Imidazolinderivates und dessen Saeureadditionssalzen
DE1150180B (de) * 1962-04-12 1963-06-12 Merck Ag E Mittel zur Vorbehandlung der Haut fuer die Rasur
US3377247A (en) * 1967-04-28 1968-04-09 Dow Chemical Co Antidepressant method
US3586695A (en) * 1968-01-26 1971-06-22 Dow Chemical Co Substituted imidazolinyl indoles
BE754935A (fr) * 1969-08-13 1971-02-17 Hoechst Ag 2-(thienyl-3'-amino)-1,3-diazacycloalcenes et leur preparation
US3622579A (en) * 1969-08-28 1971-11-23 Boehringer Sohn Ingelheim Derivatives of 2-anilino-1,3-diazacyclopentene-(2)
US3818094A (en) * 1969-08-28 1974-06-18 Boehringer Sohn Ingelheim Hypotensive pharmaceutical compositions containing certain 2-anilino-1,3-diazacyclopentenes-(2)
US3660423A (en) * 1970-02-13 1972-05-02 Dow Chemical Co 2-(substituted benzyl)methyl-2-imidazolines
DE2046785A1 (en) * 1970-09-23 1972-03-30 Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen Basic mono-azo dyes - for synthetic fibres, cotton silk, leather, paper and paints
GB1333471A (en) * 1971-01-27 1973-10-10 Labaz Imidazoline derivatives and process for preparing the same
US4125620A (en) * 1974-10-01 1978-11-14 Boehringer Ingelheim Gmbh 2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof
US3992403A (en) * 1975-05-30 1976-11-16 Schering Corporation 2-Imidazolines and their use as hypoglycemic agents
GB1538097A (en) * 1976-01-26 1979-01-10 Lafon Labor Substituted phenyl-amidines
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
US4665095A (en) * 1985-12-11 1987-05-12 Abbott Laboratories Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
US5610174A (en) * 1995-06-02 1997-03-11 Synaptic Pharmaceutical Corporation Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence
US5969137A (en) * 1996-09-19 1999-10-19 Virginia Commonwealth University Benzylamidine derivatives with serotonin receptor binding activity
US5866579A (en) * 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
ATE293102T1 (de) * 1998-04-23 2005-04-15 Takeda Pharmaceutical Naphthalene derivate ,ihre herstellung und verwendung
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
KR100492252B1 (ko) * 2002-08-09 2005-05-30 한국화학연구원 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법
WO2006119411A1 (en) * 2005-05-03 2006-11-09 Bayer Cropscience Ag Insecticidal substituted aminoalkyl heterocyclic and heteroaryl derivatives

Also Published As

Publication number Publication date
JP5167265B2 (ja) 2013-03-21
CN101528709A (zh) 2009-09-09
US20080096906A1 (en) 2008-04-24
AU2007312389A1 (en) 2008-04-24
ZA200902279B (en) 2010-03-31
ATE462696T1 (de) 2010-04-15
WO2008046756A1 (en) 2008-04-24
IL197872A0 (en) 2009-12-24
KR20090055640A (ko) 2009-06-02
KR101172940B1 (ko) 2012-08-10
PE20080984A1 (es) 2008-07-19
BRPI0718059A2 (pt) 2013-11-05
IL197872A (en) 2012-12-31
CN101528709B (zh) 2012-02-01
AU2007312389B2 (en) 2012-02-23
NO20091480L (no) 2009-04-30
RU2009112495A (ru) 2010-11-27
JP2010506874A (ja) 2010-03-04
CA2665255A1 (en) 2008-04-24
MX2009003887A (es) 2009-04-22
AR063326A1 (es) 2009-01-21
EP2076496A1 (de) 2009-07-08
TW200835494A (en) 2008-09-01
ES2340223T3 (es) 2010-05-31
CL2007002970A1 (es) 2008-05-30
EP2076496B1 (de) 2010-03-31

Similar Documents

Publication Publication Date Title
DE602007005671D1 (de) Aminomethyl-2-imidazole mit affinität zu mit dem trace-amin assoziierten rezeptoren
DE602007003427D1 (de) Motorrad
ITRM20070190A1 (it) Motorcycle
DK2315696T3 (da) Cykel
DE602007003411D1 (de) Motorrad
BRPI0719715A2 (pt) Estrutura composta
DE602007001442D1 (de) Motorrad
BRPI0812991A2 (pt) Utilização de combustível melhorado
DE602009000049D1 (de) Motorrad
DE602009001140D1 (de) Motorrad
DE602007000714D1 (de) Motorrad
DE602008001961D1 (de) Motorrad
BRPI0914664A2 (pt) motocicleta
DE602009000236D1 (de) Motorrad
DE602009000066D1 (de) Motorrad
DK2097309T3 (da) Cykelgenerator
DE602007002436D1 (de) Motorrad
DE602007011150D1 (de) Motorrad
DE602007001380D1 (de) Motorrad
DE602007008589D1 (de) Pyridooxazepin-progesteronrezeptor-modulatoren
DE602007011149D1 (de) Kraftstoffleitungsstruktur
BRPI0916313A2 (pt) motocicleta
FR2915728B1 (fr) Trotinette
ITMI20060080A1 (it) Bicicletta integrale
DE602008001051D1 (de) Motorrad

Legal Events

Date Code Title Description
8364 No opposition during term of opposition